Ascendis Pharma A/S (NASDAQ:ASND) Shares Sold by Summit Partners Public Asset Management LLC

Summit Partners Public Asset Management LLC lessened its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 46.5% in the third quarter, HoldingsChannel reports. The firm owned 55,101 shares of the biotechnology company’s stock after selling 47,872 shares during the quarter. Summit Partners Public Asset Management LLC’s holdings in Ascendis Pharma A/S were worth $8,227,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in ASND. Signaturefd LLC grew its holdings in shares of Ascendis Pharma A/S by 13.2% during the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after buying an additional 80 shares in the last quarter. Pursue Wealth Partners LLC purchased a new position in shares of Ascendis Pharma A/S during the third quarter valued at approximately $217,000. Searle & CO. acquired a new stake in Ascendis Pharma A/S during the second quarter worth approximately $205,000. Rhumbline Advisers grew its stake in Ascendis Pharma A/S by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock worth $209,000 after acquiring an additional 143 shares during the period. Finally, Algert Global LLC raised its holdings in Ascendis Pharma A/S by 54.6% in the 2nd quarter. Algert Global LLC now owns 2,180 shares of the biotechnology company’s stock valued at $297,000 after acquiring an additional 770 shares during the last quarter.

Ascendis Pharma A/S Trading Up 1.3 %

Shares of NASDAQ ASND opened at $136.32 on Friday. The stock has a fifty day moving average price of $132.55 and a 200 day moving average price of $132.21. Ascendis Pharma A/S has a 12-month low of $90.13 and a 12-month high of $161.00. The company has a market cap of $8.27 billion, a P/E ratio of -16.87 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The firm had revenue of $38.75 million during the quarter, compared to the consensus estimate of $94.74 million. On average, sell-side analysts forecast that Ascendis Pharma A/S will post -7.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ASND has been the topic of several analyst reports. StockNews.com upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Evercore ISI lifted their price target on Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a report on Tuesday, September 17th. Jefferies Financial Group upped their price objective on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a “buy” rating in a research note on Tuesday, August 13th. TD Cowen decreased their target price on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Finally, Stifel Nicolaus upped their price target on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Ascendis Pharma A/S has a consensus rating of “Moderate Buy” and a consensus target price of $191.77.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.